Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

NCT: NCT04770701 · WITHDRAWN

NCT IDNCT04770701
StatusWITHDRAWN
Start Date2020-09-20
Completion2026-06-06
SponsorTrieu, Nguyen Thi, M.D. (INDIV)
First posted
Last updated

Brief Summary

This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.

Frequently Asked Questions

What is Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes?

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes is a clinical trial registered under NCT04770701. Current status: WITHDRAWN.

What is the status of NCT04770701?

The current status of NCT04770701 (Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes) is: WITHDRAWN.

When did Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes start?

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes started on 2020-09-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑